To examine the impact of homozygous genetic disruption of IRS-1 (IRS-1 -/-) or IRS-2 (IRS-2 -/-) on basal and insulin stimulated carbohydrate and lipid metabolism in vivo we infused 18-h fasted mice (WT, IRS1 -/-and IRS2 -/-) with [3-3 H]glucose and [ 2 H 5 ]glycerol and assessed rates of glucose and glycerol turnover under basal (0-90 min) and hyperinsulinemic-euglycemic clamp (90-210 min; 5 mM glucose and 5 mU insulin*kg -1 *min -1 )
Introduction
Insulin receptor substrate (IRS) proteins mediate the pleiotropic effects of insulin on cellular function including the regulation of glucose transport and protein metabolism and the control of cell growth and survival (1, 2) . A family of at least four IRS proteins has been identified, potentially allowing for a diverse and flexible response to insulin stimulation (3) (4) (5) (6) . However, the distinct role(s) of the individual IRS proteins have yet to be fully described. To characterize the precise physiological roles of these proteins, we and others have generated mice with targeted disruption of IRS-1, IRS-2, IRS-3 or IRS-4 (3-6) and initial studies are beginning to reveal functional differences between these molecules. For example, IRS1 -/-mice are severely growth retarded, have normal fasting blood glucose concentrations and appear to be mildly insulin resistant, as suggested by insulin tolerance testing (7, 8) . In contrast, IRS2 -/-mice are normal in size but develop diabetes due to a combination of peripheral and hepatic insulin resistance and a failure in B-cell function (9, 10) . These dramatic phenotypes contrast with the absence of major abnormalities of insulin signaling in mice lacking either IRS-3 or IRS-4 (11, 12) . Thus it appears that IRS-1 and IRS-2 are major mediators of insulin action but their relative contribution to the in vivo regulation of carbohydrate and lipid metabolism has not yet been determined.
In order to examine the tissue specific roles of IRS-1 and IRS-2 in mediating insulin's effect in the key insulin responsive organs (muscle, liver and adipose) we performed hyperinsulinemic-euglycemic clamps in conscious mice in combination with the infusion of [3-3 H]glucose and [ 2 H 5 ] glycerol tracers to assess rates of glucose and glycerol turnover as well as rates of insulin-stimulated liver and muscle glycogen synthesis. These studies demonstrate that, in vivo, IRS-1 appears to have its major role in muscle alone whereas IRS-2 mediates insulin action in liver, fat and muscle.
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Experimental Procedures
Materials: Unless noted, chemicals were purchased from Sigma-Aldrich (St. Louis, MO). [ 2 H 5 ] Glycerol (98 atom percent excess) and [2-13 C]glycerol (99 atom percent excess) were purchased from Cambridge Isotopes (Andover, MA). [3-3 H]Glucose was purchased from New England Nuclear (Boston, MA). GC-MS supplies were purchased from Hewlett-Packard (Wilmington, DE). Bis(tri-methylsilyl)trifluoroacetamide+10% trimethylchlorosilane (TMS) was purchased from Pierce (Rockford, IL).
In vivo studies: Male mice (wild type, IRS-1 -/-, or IRS-2 -/-) were received from Dr. Morris F. White (Joslin Diabetes Center, Boston, MA). Catheters were implanted in the jugular vein of 5-6 week old mice, approximately 5 days prior to the study.
Mice were fasted 18 hour and infused with [ 2 H 5 ] glycerol (3 umol*kg -1 *min -1 ) to estimate rates of lipolysis and Total liver and muscle glycogen concentration was determined according to the method of Walaas and Walaas et al.
(13) with minor modifications. A portion of the hydrolyzed glycogen was also used to determine the total counts of 3 H.
Plasma insulin was assayed using the rat RIA from Linco, with the mouse standard.
Calculations: The rate of appearance of glucose and glycerol were calculated from Tracer Infusion Rate / Labeling of Plasma Pool
In the case of [3-3 H] glucose the tracer infusion rate is in dpm*kg -1 *min -1 and labeling of plasma pool is in dpm*umol glucose -1 . In the case of [ 2 H 5 ] glycerol the tracer infusion rate is in umol*kg -1 *min -1 and the labeling of plasma pool is the 2 H-enrichment of plasma glycerol.
The rate of hepatic glycogen synthesis was estimated from (umol glucose equivalent / g wet wt / 120 min clamp)
The rate of muscle glycogen synthesis was estimated from (dpm / g wet wt) / (Specific activity plasma glucose x 120 min clamp) Data are presented as the mean±sem. Statistics were calculated using one-way analysis of variance, Tukey's post hoc testing was used to determine significance. Where paired data were analyzed a t-test was used.
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Results
Insulin action on glucose and lipid metabolism in vivo was examined before and during a 2 hour hyperinsulinemiceuglycemic clamp in conscious wild-type (WT), IRS-1 -/-and IRS-2 -/-mice, and before the development of fasting hyperglycemia in the IRS-2 -/-animals. Basal plasma glucose concentrations were similar in mice from all three genotypes (Table 1) . Likewise glucose production rates were comparable in all three groups during the basal period ( Table 1) . From separate studies we have determined that fasting (18 h) insulin levels in 4 week old mice were WT 10.5 ± 0.79 uU*ml -1 , IRS1 -/-54±7 uU*ml -1 and IRS2 -/-30±2.5 uU*ml -1 mice (n=6 for each group).
The observation of basal hyperinsulinemia in IRS-1 -/-and IRS-2 -/-mice (p<0.05 for each vs WT) confirm that both IRS-1 -/-and IRS-2 -/-mice are insulin resistant. Also, IRS-1 -/-are insulin resistant as compared to IRS-2 -/-mice (p<0.05).
During the hyperinsulinemic-euglycemic clamp the glucose infusion rate was 189±30 umol*kg -1 *min -1 in WT mice (Table 1) . During the clamp WT mice exhibited a 70±20% increase in their rate of whole-body glucose utilization (p<0.05 vs basal) ( Figure 1A ). However, in both the IRS-1 -/-mice and the IRS-2 -/-mice there was a significantly attenuated response to insulin with steady state glucose infusion rates being markedly reduced, i.e.
64±19 umol*kg -1 *min -1 in IRS1 -/-mice (p<0.05 vs WT) and 28±6 umol*kg -1 *min -1 in IRS-2 -/-(p<0.05 vs WT) (Table 1) . Additionally, both IRS-1 -/-and IRS-2 -/-mice failed to show significant changes in rates of whole-body glucose utilization during the clamp ( Figure 1A ; IRS-1 -/-mice 8±8% and IRS-2 -/-mice 11±12% increases from basal in each group, respectively, p=N.S. for each from basal). Furthermore, there was a trend towards a lower glucose infusion rate in IRS-2 -/-mice vs IRS-1 -/-mice (p=0.10) suggesting that animals lacking IRS-2 display more profound defects in insulin action (Table 1) . Thus these findings confirm that IRS-2 -/-mice are markedly insulin resistant and demonstrate for the first time that IRS-1 -/-mice, studied in vivo using a hyperinsulinemic-euglycemic clamp, also display significant insulin resistance.
Skeletal muscle, liver and fat are the major sites of insulin action. To gain an insight into tissue specific differences in IRS function underlying the observed insulin resistance in IRS-1 -/-and IRS-2 -/-mice, muscle and liver glycogen metabolism, hepatic glucose production and whole-body lipid turnover were analyzed. Following the hyperinsulinemic-euglycemic clamp there were no significant differences in muscle glycogen content among the three genotypes, although there was a trend to lower muscle glycogen stores in the IRS-1 -/-mice compared to
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wild-type animals (WT mice: 0.57±0.07 mmol glucose equivalents*g wet wt -1 ; IRS-1 -/-0.43±0.03 mmol glucose equivalents*g wet wt -1 , p=0.084 vs WT; IRS-2 -/-0.71±0.17 mmol glucose equivalents*g wet wt -1 p=N.S. vs WT). In WT mice the rate of 3 H-glucose incorporation into muscle glycogen was 0.3 umol*kg -1 *min -1 .
Both IRS-1 -/-and IRS-2 -/-mice synthesized significantly less muscle glycogen during the clamp (IRS-1 -/-0.08 umol*kg -1 *min -1 , p<0.05 vs WT and IRS-2 -/-0.15 umol*kg -1 *min -1 , p<0.05 vs WT). Furthermore, IRS-1 -/-mice synthesized significantly less glycogen than IRS-2 -/-mice (p<0.05) reflecting a more significant impairment in insulin-action in the muscle of these mice.
To analyze the contribution of defective insulin signaling in the liver to insulin resistance in IRS-1 -/-and IRS-2 -/-mice hepatic glucose production was determined. In the basal state, endogenous glucose production was similar in animals of all three genotypes (Table 1) . During the hyperinsulinemic-euglycemic clamp, we observed a 59±11% decrease in endogenous glucose production in WT mice (p<0.05 vs basal glucose production rate) ( Figure 1B) .
Likewise, IRS-1 -/-mice displayed a 34±12% decrease in endogenous glucose production (p<0.05 vs basal) ( Figure 1B) , achieving a similar level of suppression to that observed in WT mice. In contrast, there was no significant effect of the hyperinsulinemic-euglycemic clamp on the rate of endogenous glucose production in IRS-2 -/-mice (12±9% decrease in glucose production, p=N.S. vs basal) ( Figure 1B) .
Analysis of hepatic glycogen metabolism in the three groups of mice revealed differences in the roles of IRS-1 and IRS-2 in liver. IRS-1 -/-mice had a slight reduction in hepatic glycogen content compared to WT animals (WT 3.58±1.27 mmol glucose equivalents*g wet wt -1 vs IRS-1 -/-mice 2.31±0.90 mmol glucose equivalents*g wet wt -1 p= N.S.). In contrast, IRS-2 -/-mice had markedly reduced hepatic glycogen (0.52±0.13 mmol glucose equivalents*g wet wt -1 , p<0.05 vs WT mice and IRS-1 -/-mice). Extrapolating from the glycogen content at the end of the clamp and the duration of the clamp we estimated rates of hepatic glycogen synthesis. The rate of insulin stimulated hepatic glycogen synthesis in WT mice was 30±11 µmol glucose@g -1 @min -1 . The rate of glycogen synthesis in IRS-1 -/-mice was 19±8 umol*kg -1 *min -1 , which was not significantly different from WT mice. In contrast, the rate of insulin stimulated hepatic glycogen synthesis was significantly reduced in IRS-2 -/-mice (4±1 umol*kg -1 *min -1 , p<0.05 vs WT mice or IRS-1 -/-mice). Thus these findings demonstrate marked defects in insulin action in vivo in the liver of the IRS-2 -/-mice.
To determine the effects of deletion of IRS-1 and IRS-2 on lipid metabolism in vivo, we analyzed plasma glycerol and FFA concentrations and the rate of glycerol production both basally and during the clamp. Basal plasma glycerol and the basal rate of glycerol production were similar in mice from each group (Table 1 ). In addition in mice of all three genotypes there was no change in the concentration of plasma glycerol in response to insulin.
During the hyperinsulinemic-euglycemic clamp there was a comparable reduction in the rate of production of glycerol in WT mice and in IRS-1 -/-mice (WT mice 28±9% reduction, IRS-1 -/-mice 30±12% reduction; p<0.05 vs basal period for each group). In contrast, we observed no reduction in the rate of production of glycerol in IRS-2 -/-mice during the hyperinsulinemic-euglycemic clamp with only a 5±6% decrease from the basal period being achieved (p=N.S. vs basal period).
Basal plasma FFA concentrations were similar in each group (Table 1) . During the hyperinsulinemic-euglycemic clamp there was a 48±3% reduction in the concentration of FFA in WT mice and a 53±4% reduction in the concentration of FFA in IRS-1 -/-mice (p<0.05 vs basal concentration in each). In contrast, we observed only a minor reduction in the concentration of plasma FFA in IRS-2 -/-mice during the hyperinsulinemic-euglycemic clamp (i.e. only a 17±7% decrease, p=N.S. from basal concentrations). Taken together these findings suggest that IRS-2 plays a major role in regulating lipid metabolism in vivo in mice.
Discussion
The role of IRS proteins as mediators of insulin signaling is well established (1,2). However, in spite of the structural similarities between IRS-1 and IRS-2 and their co-expression in insulin-sensitive tissues, it has been shown that disruption of these proteins in mice yields distinct phenotypes (7) (8) (9) (10) . While the development of diabetes in IRS-2 -/-mice at least in part reflects the role of IRS-2 in beta $-cell function, it is less clear whether IRS-1 and IRS-2 play redundant or selective roles in mediating insulin action in insulin-sensitive tissues in vivo (9, 10) . Thus in this study we determined the insulin responsiveness of carbohydrate and lipid metabolism in WT, IRS-1 -/-and normoglycemic IRS-2 -/-mice in vivo to evaluate the functional roles of IRS-1 and IRS-2 in muscle, liver and fat. Our findings demonstrate that in vivo IRS-1 mediates insulin action in skeletal muscle while IRS-2 plays important roles in liver, muscle and adipose tissue.
The deletion of IRS-1 or IRS-2 causes profound resistance to insulin stimulated whole-body glucose utilization in vivo ( Figure 1A) . Deletion of IRS-1 causes a marked defect in insulin-stimulated muscle glycogen synthesis. This is consistent with the previously reported finding of a 50% reduction in insulin-stimulated glucose transport in isolated skeletal muscle preparations (14) . In contrast, deletion of IRS-2 has a small yet significant effect on insulin
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stimulated muscle glycogen synthesis. We have previously shown that in vitro the absence of IRS-2 does not significantly impair insulin-stimulated glucose uptake in muscle (15) . Although those observations were made in a distinct experimental model (15) they suggest that IRS-2 has a role in regulating glycogen synthesis distinct from mediating insulin-stimulated glucose transport in skeletal muscle. Taken together, our previous findings (14,15) and our current observations, suggest that in vivo IRS-1 has a more important role than IRS-2 in the overall regulation of carbohydrate metabolism in muscle. Consistent with these observations Kido et al. (16) have recently demonstrated that mice with a combined heterozygous disruption of the insulin receptor and IRS-1 (IR +/-/IRS-1 +/-) develop severe muscle insulin resistance and a reduction in insulin-stimulated phosphatidylinositol-3-kinase activation, the major signaling mediator of glucose transport and glycogen synthesis (16) . In contrast, the muscle defects in IR +/-/IRS-2 +/-mice in these parameters are less marked (16) .
It is well established that the regulation of hepatic glucose production by insulin is a major determinant of blood glucose concentrations (17) . To further dissect the nature of the insulin resistance in IRS-1 -/-and IRS-2 -/-mice we examined hepatic carbohydrate metabolism. Basal endogenous glucose production was similar in WT, IRS-1 -/-and IRS-2 -/-mice (Table 1) . Endogenous glucose production decreased by approximately 60% during the infusion of 5 mU insulin*kg -1 *min -1 in overnight fasted WT mice ( Figure 1B) . These data are consistent with the results of Shen et al. (18) who reported a dose-response of insulin to glucose fluxes in awake mice.
Insulin mediated suppression of endogenous glucose production was similar in WT and IRS-1 -/-mice ( Figure 1B ).
In contrast, there was virtually no response to endogenous glucose production in IRS-2 -/-mice ( Figure 1B) . We have recently reported (9) a normal response of endogenous glucose production in IRS-2 -/+ mice, infused with 2.5 mU insulin*kg -1 *min -1 , as compared to virtually no response to endogenous glucose production in IRS-2 -/-mice. In that study (9) we observed that endogenous glucose production was almost completely suppressed at 20 mU insulin*kg -1 *min -1 in IRS-2 -/-mice suggesting that the insulin resistance can be overcome at supraphysiological insulin concentrations.
Coupled with our previous data (9), our current findings suggest that deletion of IRS-2 profoundly impairs hepatic carbohydrate metabolism in vivo. Furthermore our current observations on hepatic glycogen metabolism show defects in glycogen synthesis which are significantly more marked in IRS-2 -/-mice compared to the relatively mild abnormalities in the IRS-1 -/-mice. These findings are consistent with our analysis of phosphatidyinositol-3-kinase activation in the livers of IR +/-/IRS-2 +/-and IR +/-/IRS-1 +/-mice and the analysis of IR deficient hepatocyte cell lines (16, 19) .
There is increasing evidence that adipose tissue (e.g. presumably the release of free fatty acids) may modulate the
functions of muscle, liver and beta cell (20, 21) . Indeed we have recently shown that lipid abnormalities impair insulin action in muscle (22, 23) . The data presented here show that plasma FFA and glycerol concentrations and glycerol production were comparable in WT, IRS-1 -/-and IRS-2 -/-mice suggesting that basal lipolysis rates were similar in animals from all three genotypes (Table 1 
